Vancin-S Drug Interactions

Vancin-S 125 mg: Ototoxic and nephrotoxic drugs: Because of the possibility of additive toxicities, the concurrent or sequential systemic or topical use of other ototoxic and/or nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, bacitracin, cisplatin, colistin, polymyxin B, ciclosporin, and loop diuretics) and Vancomycin requires careful serial monitoring of renal and auditory function.
Bile acid sequestrants: May diminish the therapeutic effect of Vancomycin. Avoid concurrent administration of oral Vancomycin and bile acid sequestrants when possible. If use of both agents is necessary, consider separating doses by at least 2 hours to minimize the significance of the interaction.
Nonsteroidal anti-inflammatory drugs (NSAIDs): May increase the serum concentration of Vancomycin.
Colistimethate: Vancomycin may enhance the nephrotoxic effect of colistimethate.
Piperacillin: Piperacillin may enhance the nephrotoxic effect of Vancomycin.
Sodium picosulfate: Vancomycin may diminish the therapeutic effect of sodium picosulfate. Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using Vancomycin.
Neuromuscular-blocking agents: Vancomycin may enhance the neuromuscular-blocking effect of neuromuscular-blocking agents.
BCG (intravesical) and BCG vaccine (immunization): Vancomycin may diminish the therapeutic effect of BCG (intravesical)/BCG vaccine (immunization).
Typhoid vaccine: Vancomycin may diminish the therapeutic effect of typhoid vaccine. Only the live attenuated Ty21a strain is affected. Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with Vancomycin. Use of this vaccine should be postponed until at least 3 days after cessation of Vancomycin.
Vancin-S: Anesthesia. Concomitant use w/ aminoglycoside and other neurotoxic/nephrotoxic drugs may increase nephrotoxicity.